We observed a lack of consistency in the application of methods for computing MID or MCID for generic and disease-specific HRQoL measures .
The anchor-based method yields conservative estimates of MID or MCID , compared to the distribution-based method .
OBJECTIVES The objective of the study was to assess the usability of minimal important difference ( MID ) and minimal clinical ly important difference ( MCID ) for measuring meaningful changes in disease-specific and generic health-related quality -of-life ( HRQoL ) outcomes in patient-centered care .
Interpreting changes in quality-of-life score in N of 1 randomized trials.
To provide additional evidence regarding the plausible range of the differences in health-related quality of life ( HRQL ) question naire scores within which the minimal important difference ( MID ) falls , we review ed the results of 32 r and omized controlled trials in individual subjects ( N of 1 RCTs ) with chronic diseases . These trials had been conducted to establish whether a patient was obtaining more good than harm from a medication . Each N of 1 RCT included a series of pairs of treatment periods , one period on active drug , and one on placebo or alternative drug . We examined the relationship between small ( MID ) , medium , and large differences between periods within pairs , as indicated by Global Ratings and differences between these same periods according to HRQL question naires . The results showed a mean difference of 0.29 points per question in HRQL question naire scores corresponded to the MID . Differences of approximately 0.66 points per question corresponded to a moderate difference as ranked by the Global Rating ; difference of about 1.09 points per question represented marked difference
We observed a lack of consistency in the application of methods for computing MID or MCID for generic and disease-specific HRQoL measures .
The anchor-based method yields conservative estimates of MID or MCID , compared to the distribution-based method .
OBJECTIVES The objective of the study was to assess the usability of minimal important difference ( MID ) and minimal clinical ly important difference ( MCID ) for measuring meaningful changes in disease-specific and generic health-related quality -of-life ( HRQoL ) outcomes in patient-centered care .